Market Overview:
The global epoprostenol sodium FDF market is expected to grow at a CAGR of XX% and reach a value of USD XX million by 2030. The market is segmented by type (0.5 mg, 1.5 mg), by application (hospital, clinic) and by region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa). The growth in the global epoprostenol sodium FDF market can be attributed to the increasing prevalence of pulmonary arterial hypertension (PAH), rising awareness about PAH treatment options among physicians and patients alike, technological advancements in the field of PAH treatment therapies and growing demand for novel therapeutics for treating PAH. However, factors such as high cost associated with novel therapies and lack of reimbursement policies are likely to restrain the growth of this market during the forecast period.
Product Definition:
Epoprostenol Sodium FDF is a synthetic prostaglandin analogue used as a vasodilator to treat pulmonary hypertension and congestive heart failure. It relaxes the smooth muscle in blood vessels, decreasing resistance to blood flow and reducing blood pressure.
0.5 mg:
Epoprostenol sodium is a prostacyclin analog used to treat pulmonary hypertension in neonates and infants. It works by relaxing constricted blood vessels, allowing more oxygenated blood flow through them. The drug has been shown to be effective in improving the survival rate of patients with pulmonary hypertension as well as reducing the need for mechanical ventilation.
1.5 mg:
1.5 mg of epoprostenol sodium is a cardioselective drug which means it preferentially targets cardiac muscle and causes vasodilation, increased oxygen delivery to the tissues, and enhanced tissue oxygenation.
It is used in patients suffering from pulmonary embolism who require immediate treatment but whose breathing can be supported by mechanical ventilation until an alternative therapy such as epoprostenol injection can be administered effectively.
Application Insights:
Clinic-based epoprostenol sodium fDF is expected to witness the fastest growth at a CAGR of XX% from 2018 to 2030 owing to its ability to treat life-threatening pulmonary hypertension and systemic embolism. Epoprostenol sodium fDF has been proven effective in the treatment of patients suffering from acute respiratory failure due largely to cardiopulmonary arrest or brain injury, which requires emergency treatment with stem cells.
The hospital-based segment held a significant share in 2017 and is expected maintain dominance throughout the forecast period owing mainly to rising awareness about organ donation among hospitalized patients as well as their families. In addition, increasing number of hospitals offering allogeneic stem cell transplantation for various life-threatening conditions such as hemophilia, acquired immune deficiency syndrome (AIDS), chronic myelogenous leukemia (CML) and other blood disorders are anticipated drive market growth over the forecast period.
Regional Analysis:
North America dominated the global epoprostenol sodium FDA approval market in 2016 with a revenue share of over 50.0%. The growth is attributed to the presence of well-established healthcare infrastructure, high per capita healthcare expenditure, and favorable reimbursement policies in this region. In addition, increasing awareness about COVID-19 among patients and physicians is expected to drive demand for prostacyclin analogues in this region.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising incidences of chronic diseases such as COPD coupled with growing geriatric population that require long term treatment for symptoms management. Moreover, improving economic conditions are also likely to contribute toward regional market growth over the next eight years.
Growth Factors:
- Increasing prevalence of pulmonary hypertension
- Growing geriatric population
- Rising awareness about the benefits of epoprostenol sodium FDF therapy
- Technological advancements in the field of pulmonary hypertension treatment
- Availability of generic versions of epoprostenol sodium FDF
Scope Of The Report
Report Attributes
Report Details
Report Title
Epoprostenol Sodium FDF Market Research Report
By Type
0.5 mg, 1.5 mg
By Application
Hospital, Clinic
By Companies
GSK, Teva
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
237
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global Epoprostenol Sodium FDF Market Report Segments:
The global Epoprostenol Sodium FDF market is segmented on the basis of:
Types
0.5 mg, 1.5 mg
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GSK
- Teva
Highlights of The Epoprostenol Sodium FDF Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 0.5 mg
- 1.5 mg
- By Application:
- Hospital
- Clinic
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Epoprostenol Sodium FDF Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Epoprostenol Sodium FDF is a medication used to treat heart failure. It works by helping the heart pump more effectively.
Some of the major companies in the epoprostenol sodium fdf market are GSK, Teva.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Epoprostenol Sodium FDF Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Epoprostenol Sodium FDF Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Epoprostenol Sodium FDF Market - Supply Chain
4.5. Global Epoprostenol Sodium FDF Market Forecast
4.5.1. Epoprostenol Sodium FDF Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Epoprostenol Sodium FDF Market Size (000 Units) and Y-o-Y Growth
4.5.3. Epoprostenol Sodium FDF Market Absolute $ Opportunity
5. Global Epoprostenol Sodium FDF Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Epoprostenol Sodium FDF Market Size and Volume Forecast by Type
5.3.1. 0.5 mg
5.3.2. 1.5 mg
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Epoprostenol Sodium FDF Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Epoprostenol Sodium FDF Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Clinic
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Epoprostenol Sodium FDF Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Epoprostenol Sodium FDF Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Epoprostenol Sodium FDF Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Epoprostenol Sodium FDF Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Epoprostenol Sodium FDF Demand Share Forecast, 2019-2026
9. North America Epoprostenol Sodium FDF Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Epoprostenol Sodium FDF Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Epoprostenol Sodium FDF Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Clinic
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Epoprostenol Sodium FDF Market Size and Volume Forecast by Type
9.7.1. 0.5 mg
9.7.2. 1.5 mg
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Epoprostenol Sodium FDF Demand Share Forecast, 2019-2026
10. Latin America Epoprostenol Sodium FDF Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Epoprostenol Sodium FDF Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Epoprostenol Sodium FDF Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Clinic
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Epoprostenol Sodium FDF Market Size and Volume Forecast by Type
10.7.1. 0.5 mg
10.7.2. 1.5 mg
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Epoprostenol Sodium FDF Demand Share Forecast, 2019-2026
11. Europe Epoprostenol Sodium FDF Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Epoprostenol Sodium FDF Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Epoprostenol Sodium FDF Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Clinic
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Epoprostenol Sodium FDF Market Size and Volume Forecast by Type
11.7.1. 0.5 mg
11.7.2. 1.5 mg
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Markt Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Epoprostenol Sodium FDF Demand Share, 2019-2026
12. Asia Pacific Epoprostenol Sodium FDF Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Epoprostenol Sodium FDF Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Epoprostenol Sodium FDF Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Clinic
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Epoprostenol Sodium FDF Market Size and Volume Forecast by Type
12.7.1. 0.5 mg
12.7.2. 1.5 mg
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Epoprostenol Sodium FDF Demand Share, 2019-2026
13. Middle East & Africa Epoprostenol Sodium FDF Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Epoprostenol Sodium FDF Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Epoprostenol Sodium FDF Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Clinic
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Epoprostenol Sodium FDF Market Size and Volume Forecast by Type
13.7.1. 0.5 mg
13.7.2. 1.5 mg
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Epoprostenol Sodium FDF Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Epoprostenol Sodium FDF Market: Market Share Analysis
14.2. Epoprostenol Sodium FDF Distributors and Customers
14.3. Epoprostenol Sodium FDF Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. GSK
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Teva
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. COMPANY3
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. COMPANY4
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. COMPANY5
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
